Decrease in naturally occurring antibodies against epitopes of Alzheimer’s disease (AD) risk gene products is associated with cognitive decline in AD

Gu, Dongmei; Wang, Luchun; Zhang, Nan; Wang, Huali; Yu, Xin

doi:10.1186/s12974-023-02750-9

Journal of Neuroinflammation

Table 2 Levels of NAbs in the CN, MCI and AD groups and correlation analysis between plasma levels of NAbs and MMSE scores in three groups

From: Decrease in naturally occurring antibodies against epitopes of Alzheimer’s disease (AD) risk gene products is associated with cognitive decline in AD

	NAbs	Comparison groups								Correlation analysis
	NAbs	CN (n = 56)	MCI (n = 16)	AD (n = 56)	F	P value	CN vs. MCI P value	CN vs. AD P value	MCI vs. AD P value	r	P value
1	ADAM10	0.20 ± 0.060	0.17 ± 0.052	0.15 ± 0.044	10.977	4.100E−05	0.130	2.300E−05	0.476	0.391	2.000E−04
2	ADAMTS1	0.26 ± 0.068	0.26 ± 0.080	0.21 ± 0.064	8.432	3.670E−04	0.912	0.001	0.013	0.277	0.002
3	BIN1	0.29 ± 0.090	0.32 ± 0.106	0.25 ± 0.083	5.183	0.007	0.517	0.038	0.018	0.219	0.015
4	CASS4	0.28 ± 0.079	0.30 ± 0.091	0.24 ± 0.076	4.959	0.008	0.757	0.024	0.038	0.215	0.016
5	CD2AP	0.22 ± 0.062	0.21 ± 0.057	0.19 ± 0.058	2.932	0.057	0.795	0.045	0.601	0.294	0.001
6	CLU	0.21 ± 0.058	0.17 ± 0.043	0.16 ± 0.040	12.568	1.100E−05	0.018	1.000E−05	0.885	0.361	3.800E−05
7	FERMT2	0.27 ± 0.063	0.23 ± 0.043	0.22 ± 0.051	10.917	4.300E−05	0.183	2.500E−05	0.552	0.297	0.001
8	INPP5D	0.25 ± 0.077	0.26 ± 0.096	0.21 ± 0.070	4.721	0.011	0.833	0.024	0.053	0.168	0.063
9	IQCK	0.27 ± 0.085	0.27 ± 0.099	0.23 ± 0.074	4.462	0.013	0.994	0.014	0.175	0.182	0.043
10	MEF2C	0.30 ± 0.082	0.32 ± 0.106	0.25 ± 0.079	6.296	0.002	0.763	0.008	0.020	0.186	0.039
11	NDUFAF6	0.35 ± 0.121	0.35 ± 0.116	0.28 ± 0.090	7.145	0.001	0.998	0.001	0.056	0.201	0.025
12	OARD1	0.19 ± 0.050	0.17 ± 0.038	0.16 ± 0.039	7.231	0.001	0.196	0.001	0.717	0.284	0.001
13	PICALM	0.19 ± 0.051	0.18 ± 0.045	0.16 ± 0.034	6.708	0.002	0.732	0.001	0.222	0.245	0.006
14	PTK2B	0.19 ± 0.046	0.17 ± 0.039	0.15 ± 0.042	10.440	6.400E−05	0.312	3.400E−05	0.257	0.269	0.003
15	SLC24A4	0.24 ± 0.067	0.21 ± 0.048	0.18 ± 0.056	10.689	5.200E−05	0.183	2.800E−05	0.395	0.284	0.001
16	SORL1	0.24 ± 0.054	0.16 ± 0.052	0.19 ± 0.066	14.667	2.000E−06	2.700E–05	1.510E–04	0.164	0.275	0.002
17	SPPL2A	0.24 ± 0.069	0.14 ± 0.028	0.19 ± 0.052	21.228	1.193E−08	4.337E−08	1.580E−04	0.004	0.341	1.240E−04
18	TREM2	0.27 ± 0.066	0.20 ± 0.036	0.20 ± 0.071	18.808	2.416E−10	1.180E−04	5.523E−09	1.000	0.441	3.800E−07
19	WWOX	0.24 ± 0.067	0.17 ± 0.028	0.19 ± 0.065	10.787	4.800E−05	0.001	0.001	0.432	0.271	0.002
20	ADAMTS4	0.22 ± 0.069	0.18 ± 0.040	0.17 ± 0.052	7.641	0.001	0.066	0.001	0.966	0.245	0.006
21	APH1B	0.21 ± 0.063	0.17 ± 0.035	0.18 ± 0.046	7.299	0.001	0.011	0.004	0.734	0.207	0.021
22	APOE	0.24 ± 0.074	0.20 ± 0.046	0.20 ± 0.058	6.044	0.003	0.105	0.003	0.983	0.223	0.013
23	CCDC6	0.24 ± 0.064	0.21 ± 0.049	0.20 ± 0.051	5.304	0.006	0.215	0.005	0.898	0.227	0.011
24	NCK2	0.26 ± 0.067	0.22 ± 0.044	0.23 ± 0.072	3.899	0.023	0.104	0.039	0.913	0.200	0.026
25	SPRED2	0.31 ± 0.086	0.21 ± 0.046	0.24 ± 0.081	15.349	1.000E−06	5.300E−05	3.200E−05	0.343	0.336	1.350E−04
26	TMEM163	0.27 ± 0.088	0.15 ± 0.036	0.20 ± 0.073	19.892	3.153E−08	7.686E−07	1.300E−05	0.068	0.323	2.510E−04
27	TSPAN14	0.26 ± 0.063	0.17 ± 0.037	0.20 ± 0.074	15.357	1.000E−06	2.200E−05	7.800E−05	0.185	0.372	2.100E−05
28	VKORC1	0.31 ± 0.099	0.16 ± 0.039	0.21 ± 0.071	29.317	3.622E−11	1.368E−08	4.149E−08	0.055	0.392	7.000E−06

Values are provided as mean ± SD. The NAbs levels in plasma of AD patients, MCI patients and CNs were compared with one-way analysis of variance (ANOVA) and Post hoc P values were determined using Tukey’s adjustment for multiple comparisons. Correlation analysis between plasma levels of NAbs and MMSE scores was analyzed using Spearman correlation analysis. P values were compared against a Bonferroni-adjusted given the number of tests per hypothesis: one for testing biomarkers against a clinical diagnosis [α = 0.05/number of tests (28), 0.002]
NAbs natural antibodies, AD Alzheimer’s disease, MCI mild cognitive impairment, CN cognitively normal controls, MMSE Mini-Mental State Examination

Back to article page

ISSN: 1742-2094

Contact us

Submission enquiries: journalsubmissions@springernature.com